ARDX250117C17000
- 0.05
- 0.000.00%
Ardelyx Newsroom
Ardelyx, Inc. (NASDAQ:ARDX): Is Breakeven Near?
Ardelyx (ARDX) Sees Its Depressed Stock Turning Around
After a Year of 1.7% Returns, Ardelyx, Inc.'s (NASDAQ:ARDX) Share Price Drop Last Week May Have Less of an Impact on Institutional Investors
Potential Growth for Ardelyx's Ibsrela Amidst Market Volatility
Express News | Ardelyx Inc : Leerink Partners Raises Target Price to $12 From $11
Insider Sale: See Remarks of $ARDX (ARDX) Sells 7,046 Shares
Independent Chairman of the Board of Ardelyx David Mott Buys 18% More Shares
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Announces Target Price $11
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Ardelyx Appoints Joseph Reilly as Principal Accounting Officer
Ardelyx Insider Bought Shares Worth $996,598, According to a Recent SEC Filing
Ardelyx Down as H.C. Wainwright Downgrades Rating on Anticipated Xphozah Sales Drop
Improved Revenues Required Before Ardelyx, Inc. (NASDAQ:ARDX) Shares Find Their Feet
H.C. Wainwright Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $5.5
Express News | Ardelyx Inc : H.c. Wainwright Cuts to Neutral,
Express News | Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
Ardelyx Is Maintained at Buy by Citigroup
Ardelyx's Strong Sales and Strategic Positioning Reinforce Buy Rating Amid Reimbursement Uncertainties
Ardelyx Price Target Lowered to $10 From $12 at Citi